CLARK IAN T — SEC Form 4 filings
SEC reporting owner CIK 1336504. 22 Form 4 filings on record with FilingPulse; latest filed 2026-08-05.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2024-06-13 to 2026-08-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 12 legs across 6 filings — 329,457 shares, $14,496,174 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 50.
- Largest priced transaction: sale of 193,056 shares @ $29.71 ($5,735,694) in Olema Pharmaceuticals, Inc., filed 2025-12-23.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | Director | 4 | — | 3 legs · 264,800 sh · $7,873,109 | 11 |
| Guardant Health, Inc. (GH) | Director | 8 | — | 9 legs · 64,657 sh · $6,623,065 | 25 |
| GoodRx Holdings, Inc. (GDRX) | Director | 3 | — | — | 5 |
| Kyverna Therapeutics, Inc. (KYTX) | Director | 2 | — | — | 4 |
| Corvus Pharmaceuticals, Inc. (CRVS) | Director | 3 | — | — | 3 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | Director | 2 | — | — | 2 |
Form 4 filings — CLARK IAN T
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-05 | 4 | Guardant Health, Inc. (GH) | Option exercise (M): 2,255 @ $91.11 · Option exercise (M): 6,833 @ $50.57 · Sale (S): 9,088 @ $158.98 · Sale (S): 5,092 @ $158.80 · Option exercise (M): 2,255 (derivative) @ $0 · Option exercise (M): 6,833 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Olema Pharmaceuticals, Inc. (OLMA) | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Guardant Health, Inc. (GH) | Option exercise (M): 5,092 @ $0 · Option exercise (M): 5,092 (derivative) @ $0 · Grant/award (A): 2,711 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Corvus Pharmaceuticals, Inc. (CRVS) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 7,490 @ $0 | EDGAR |
| 2026-05-29 | 4 | Kyverna Therapeutics, Inc. (KYTX) | Grant/award (A): 5,093 @ $0 · Grant/award (A): 20,582 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Guardant Health, Inc. (GH) | Sale (S): 6,876 @ $106.90 | EDGAR |
| 2025-12-23 | 4 | Olema Pharmaceuticals, Inc. (OLMA) | Option exercise (M): 209,690 @ $4.41 · Option exercise (M): 21,520 @ $3.61 · Option exercise (M): 21,520 @ $7.84 · Option exercise (M): 12,070 @ $4.08 · Sale (S): 29,904 @ $28.83 · Sale (S): 193,056 @ $29.71 · +5 more | EDGAR |
| 2025-12-08 | 4 | Guardant Health, Inc. (GH) | Option exercise (M): 9,105 @ $38.42 · Option exercise (M): 8,803 @ $38.01 · Option exercise (M): 10,703 @ $31.84 · Sale (S): 8,156 @ $106.67 · Sale (S): 17,055 @ $107.27 · Sale (S): 3,400 @ $108.05 · +3 more | EDGAR |
| 2025-08-05 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 7,000 @ $0 | EDGAR |
| 2025-07-09 | 4 | GoodRx Holdings, Inc. (GDRX) | Option exercise (M): 17,248 @ $4.74 · Option exercise (M): 17,248 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Guardant Health, Inc. (GH) | Sale (S): 6,672 @ $48.38 · Grant/award (A): 6,833 (derivative) @ $0 · Grant/award (A): 5,092 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Guardant Health, Inc. (GH) | Option exercise (M): 8,088 @ $0 · Option exercise (M): 8,088 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Corvus Pharmaceuticals, Inc. (CRVS) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Olema Pharmaceuticals, Inc. (OLMA) | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | GoodRx Holdings, Inc. (GDRX) | Grant/award (A): 57,050 @ $0 | EDGAR |
| 2025-06-02 | 4 | Kyverna Therapeutics, Inc. (KYTX) | Grant/award (A): 16,634 @ $0 · Grant/award (A): 65,351 (derivative) @ $0 | EDGAR |
| 2024-11-14 | 4 | Guardant Health, Inc. (GH) | Option exercise (M): 1,076 @ $4.18 · Sale (S): 1,076 @ $29.52 · Sale (S): 7,242 @ $29.44 · Other (J): 8,435 @ $0 · Other (J): 8,435 @ $0 · Option exercise (M): 1,076 (derivative) @ $0 | EDGAR |
| 2024-07-10 | 4 | GoodRx Holdings, Inc. (GDRX) | Grant/award (A): 25,852 @ $0 · Grant/award (A): 51,745 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Olema Pharmaceuticals, Inc. (OLMA) | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Corvus Pharmaceuticals, Inc. (CRVS) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Guardant Health, Inc. (GH) | Option exercise (M): 6,776 @ $0 · Option exercise (M): 6,776 (derivative) @ $0 · Grant/award (A): 10,703 (derivative) @ $0 · Grant/award (A): 8,088 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1336504 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →